Valuation Astellas Pharma Inc. OTC Markets

Stocks

ALPMY

US04623U1025

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 23:59:57 26/06/2026 +04			5-day change	1st Jan Change
13.34 ^USD	+1.44%		-0.82%	+0.38%

06-26	Lupin Receives U.S. FDA Tentative Approval for Enzalutamide Tablets	MT
06-24	Merck Wins European Commission Approval for KEYTRUDA Plus Padcev in Bladder Cancer	MT

Company Valuation: Astellas Pharma Inc.

Data adjusted to current consolidation scope

Fiscal Period: March	2022	2023	2024	2025	2026	2027	2028	2029
Market Cap ¹	3,519,738	3,381,409	2,946,773	2,589,390	4,512,563	3,842,751	-	-
Change	-	-3.93%	-12.85%	-12.13%	74.27%	-14.84%	-	-
Enterprise Value (EV) ¹	3,203,752	3,004,569	2,611,086	3,232,444	4,796,910	3,765,932	3,451,572	3,175,890
Change	-	-6.22%	-13.1%	23.8%	48.4%	-21.49%	-8.35%	-7.99%
P/E	28.5x	34.7x	173x	51x	15.5x	11.1x	11.7x	15.6x
PBR	2.39x	2.24x	1.85x	1.71x	2.47x	1.95x	1.82x	1.75x
PEG	-	-1.8x	-2.1x	0x	0x	0.6x	-2.24x	-0.6x
Capitalization / Revenue	2.72x	2.23x	1.84x	1.35x	2.11x	1.71x	1.85x	2.08x
EV / Revenue	2.47x	1.98x	1.63x	1.69x	2.24x	1.67x	1.66x	1.72x
EV / EBITDA	13.6x	12.6x	14.2x	13.5x	8.31x	5.83x	5.59x	6.19x
EV / EBIT	20.6x	22.6x	102x	78.8x	12.5x	8.21x	7.9x	9.49x
EV / FCF	14.1x	10.3x	-3.88x	20.5x	9.72x	9.15x	6.86x	7x
FCF Yield	7.08%	9.7%	-25.8%	4.87%	10.3%	10.9%	14.6%	14.3%
Dividend per Share ²	50	60	70	74	78	80.5	83.08	85
Rate of return	2.62%	3.19%	4.26%	5.12%	3.1%	3.75%	3.87%	3.96%
EPS ²	67.08	54.24	9.51	28.35	162.8	193.3	183.2	137.7
Distribution rate	74.5%	111%	736%	261%	47.9%	41.6%	45.4%	61.7%
Net sales ¹	1,296,163	1,518,619	1,603,672	1,912,323	2,139,245	2,249,053	2,079,418	1,850,465
EBITDA ¹	235,370	238,767	183,358	240,171	577,227	645,408	617,576	513,327
EBIT ¹	155,686	133,029	25,518	41,039	382,633	458,888	437,184	334,774
Net income ¹	124,086	98,714	17,045	50,747	291,535	345,804	327,284	245,607
Net Debt ¹	-315,986	-376,840	-335,687	643,054	284,347	-76,819	-391,179	-666,861
Reference price ²	1,911.00	1,883.00	1,643.50	1,446.50	2,519.00	2,145.00	2,145.00	2,145.00
Nbr of stocks (in thousands)	1,841,831	1,795,756	1,792,986	1,790,107	1,791,411	1,791,492	-	-
Announcement Date	27/04/22	27/04/23	25/04/24	25/04/25	27/04/26	-	-	-

¹JPY in Million²JPY

Estimates

P/E, Detailed evolution

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
ELI LILLY AND COMPANY	35.2x	12.84x	26.1x	0.57%	1,077B
JOHNSON & JOHNSON	27.22x	6.26x	17.02x	2.1%	613B
ABBVIE INC.	32.17x	7.47x	15.29x	2.73%	448B
ROCHE HOLDING AG	17.9x	4.45x	10.94x	2.98%	332B
ASTRAZENECA PLC	23.72x	4.94x	14x	1.76%	293B
NOVARTIS AG	21.69x	5.59x	13.51x	2.83%	286B
NOVO NORDISK A/S	14.19x	5.21x	10.72x	3.54%	215B
AMGEN INC.	23.3x	6.21x	10.84x	2.81%	193B
GILEAD SCIENCES, INC.	-45.82x	5.53x	30.47x	2.54%	159B
Average	16.62x	6.50x	16.54x	2.43%	401.79B
Weighted average by Cap.	24.44x	7.95x	18.32x	1.97%